“These data will have a clinical impact, especially against the background of the recently published data from the large randomized trial, which has shown that IL-1 antagonism in these patients lead to a significant reduction in cardiovascular mortality,” Dr. Ebrahimi said. “We also still do not know if this treatment is possibly harmful to the patient on cardiovascular outcomes.”
The investigators reported no relevant financial disclosures.
ezimmerman@frontlinemedcom.com
SOURCE: Ebrahimi F. et al. ENDO 2018, Abstract OR15-6.